Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Janet S. Graham
Observed name:
J. Graham
Institution:
Beatson West of Scotland Cancer Centre
Observed institution:
Beatson West of Scotland Cancer Centre
ORCID:
0000-0002-2048-2698
Observed ORCID:
0000-0002-2048-2698
OpenAlex ID:
A5002476541
Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
2026
·
Lily V.S. Hillson
, Ross K. McMahon
, et al.
·
Clinical Cancer Research
·
11
164P Roginolisib (IOA-244), the first highly selective oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ), has immuno-modulatory effects associated with clinical benefits in patients with metastatic uveal melanoma
2024
·
A.M. Di Giacomo
, M. Simonelli
, et al.
·
Immuno-Oncology Technology
·
3
PDF
626P Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma
2024
·
A.M. Di Giacomo
, M. Simonelli
, et al.
·
Annals of Oncology
·
2
PDF
192P Safety and clinical activity of IOA-244: A highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study
2022
·
A.M. Di Giacomo
, F. Santangelo
, et al.
·
Immuno-Oncology Technology
·
2
Figure S1 from Differential Immunologic Effects of Short-Course and Long-Course Radiotherapy in Locally Advanced Rectal Cancer
2026
·
Lily V.S. Hillson
, Ross K. McMahon
, et al.
131P Safety and clinical efficacy of roginolisib (IOA-244): The first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ)
2023
·
A.M. Di Giacomo
, M. Simonelli
, et al.
·
Immuno-Oncology Technology
PDF
Show more works
View as search
Works count:
6
Citation count:
18
H-index:
2
I10-index:
1
Year
Topic
Type